drugset / Trial / NCT00860522

JVRS-100 for the Treatment of Patients With Relapsed or Refractory Leukemia

NCT00860522

Phase 1 Completed 11 enrolled Milton S. Hershey Medical Center
Non-randomizedCrossoverOpen-labelTreatment

Summary

This is a Phase 1, open-label, dose escalation study of JVRS-100. The study will proceed in 2 stages to minimize the number of patients treated at doses substantially below the recommended phase 2 dose. In stage 1, an accelerated titration schema will be followed with one patient at each dose level. Stage 2 will commence after a dose limiting toxicity is observed in stage 1 or after the maximum dose for stage 1 is reached. Stage 2 will follow a modified Fibonacci schema with 3-6 subjects at each dose level until a recommended phase 2 dose is determined. The cohort will then be expanded to a maximum of 12 patients to more fully evaluate the recommended phase 2 dose.

Timeline

Start
2009-03-01
Primary completion
2014-10-31
Completion
2017-02-20

Drugs

EvaluationDrugModalityDoseRoute
Subject JVRS-100 Unknown 0.5 ug/kg
Subject JVRS-100 Unknown 1 ug/kg
Subject JVRS-100 Unknown 2 ug/kg
Subject JVRS-100 Unknown 4 ug/kg

Indications